The epidermal growth factor receptor pathway: a model for targeted therapy.
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase receptor that is frequently expressed in epithelial tumors. The EGFR was the first receptor to be proposed as a target for cancer therapy, and after 2 decades of intensive research, there are several anti-EGFR agents available in the clinic. Recent advances in our understanding in the mechanisms of receptor activation and function, discovery of primary and secondary EGFR somatic mutations, as well as a new generation of anti-EGFR agents provide new leads on the clinical targeting of this receptor and may serve as a model for strategies aimed at targeting other receptors.
Scaltriti
Maurizio
M
Medical Oncology Service, Vall d'Hebron University Hospital and Universidad Autónoma de Barcelona, Barcelona, Spain.
Baselga
José
J
D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000502:physiology*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000502:physiology; D011905:Genes, ras / Q000502:physiology; D006801:Humans; D008954:Models, Biological; D009154:Mutation / Q000502:physiology; D051058:Oncogene Protein v-akt / Q000502:physiology; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology; D050791:STAT Transcription Factors / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology*; D048490:raf Kinases / Q000502:physiology; D019061:src-Family Kinases / Q000502:physiology
D050791:STAT Transcription Factors; D019869:Phosphatidylinositol 3-Kinases; D066246:ErbB Receptors; D019061:src-Family Kinases; D051058:Oncogene Protein v-akt; D048490:raf Kinases; D048049:Extracellular Signal-Regulated MAP Kinases